Aerie Pharmaceuticals initiates netarsudil ophthalmic solution phase 2 clinical trial
Aerie Pharmaceuticals announced the commencement of patient dosing in its Phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA to support potential regulatory submission of netarsudil ophthalmic solution in Japan. March 21, 2019